ADCY6

ADCY6 (AC6) is a transmembrane adenylyl cyclase that generates cAMP downstream of G-protein-coupled receptor stimulation and serves as a node where receptor signaling and intracellular calcium are integrated to control diverse epithelial, secretory, and cardiac processes (PMID:17068292, PMID:20466003). In renin-producing juxtaglomerular cells, AC6 acts as the enzymatic link coupling elevated intracellular calcium to reduced cAMP and suppressed renin release (PMID:17068292), while in kidney collecting ducts it supplies the vasopressin V2 receptor-stimulated cAMP required for water reabsorption (PMID:20466003). AC6-derived cAMP operates through PKA/CREB-dependent programs in multiple tissues: it is transcriptionally upregulated by direct Purβ binding to its promoter to drive hepatic glucose production (PMID:31918924), and is required for peripheral nervous system myelination, where a homozygous missense mutation causes loss of PNS myelin in humans (PMID:24319099). AC6 generates a spatially distinct, lipid-raft-associated cAMP pool that preferentially phosphorylates autophagy, Ca2+/calmodulin, Rho GTPase, and cytoskeletal targets (PMID:36926196), and it physically associates with CFTR at the apical intestinal surface to form the principal cAMP-generating complex driving cholera toxin-induced fluid secretion (PMID:29903911). Beyond canonical cAMP production, AC6 controls airway ciliary length by inhibiting AMPK-mediated autophagic degradation of the kinesin KIF19A (PMID:32683324), and exerts cAMP-independent protective effects in cardiac myocytes—reducing hypertrophy and apoptosis—demonstrated by a catalytically inactive D426A mutant that reproduces these phenotypes without increasing cAMP (PMID:21127130).

1. 2006 High

   Established AC6 as the enzymatic link translating elevated intracellular calcium into reduced cAMP and suppressed renin release, defining its calcium-inhibitable cyclase behavior in a physiological setting.

   Evidence siRNA knockdown of AC5/AC6 in primary juxtaglomerular cells and As4.1 cells with cAMP measurement and permeable cAMP analog rescue

   PMID:17068292

   Open questions at the time

   • Does not resolve the relative contribution of AC5 versus AC6
   • Mechanism of calcium-mediated inhibition of AC6 not structurally defined
2. 2010 High

   Showed AC6 is required for V2 receptor-stimulated cAMP in the kidney, placing it in renal water homeostasis and demonstrating a non-redundant GPCR-coupled role in vivo.

   Evidence AC6 knockout mice with adenylyl cyclase activity assays, metabolic cage, and DCE-MRI

   PMID:20466003

   Open questions at the time

   • Does not identify the downstream aquaporin trafficking steps
   • Tissue-specific contributions within the nephron not dissected
3. 2010 High

   Demonstrated that AC6 amplifies catecholamine/prostacyclin-stimulated cAMP to inhibit collagen synthesis, linking AC6 to anti-fibrotic signaling.

   Evidence Fibroblast AC6 overexpression with cAMP and collagen assays, plus FTS1-AC6 transgenic mice in bleomycin lung fibrosis

   PMID:20348281

   Open questions at the time

   • Receptor selectivity (isoproterenol/beraprost but not PGE2/butaprost) mechanism unexplained
   • Endogenous AC6 contribution not tested by loss-of-function
4. 2010 High

   Revealed a cAMP-independent function of AC6 in cardiac myocytes, since a catalytically dead D426A mutant still reduced hypertrophy and apoptosis, separating enzymatic from non-enzymatic roles.

   Evidence Adenoviral transfer of AC6 and D426A mutant in adult rat cardiac myocytes with cAMP, hypertrophy, apoptosis, and Ca2+ transient readouts

   PMID:21127130

   Open questions at the time

   • Molecular effector of the cAMP-independent activity unidentified
   • Whether D426A retains residual cyclase output sufficient for some effects not fully excluded
5. 2013 Medium

   Connected ADCY6 to peripheral nervous system myelination through human genetics and zebrafish knockdown, establishing an essential developmental role.

   Evidence Whole exome sequencing identifying a homozygous missense mutation, sciatic nerve electron microscopy, and zebrafish morpholino knockdown

   PMID:24319099

   Open questions at the time

   • cAMP pathway involvement inferred, not directly demonstrated
   • Morpholino specificity limitations
   • Schwann-cell-autonomous versus axonal requirement unresolved
6. 2016 Medium

   Placed AC6 downstream of HSF1 in a transcriptional axis ameliorating pressure-overload heart failure, linking stress-responsive transcription to AC6/cAMP/PKA output.

   Evidence TAC model with HSF1 transgenic and knockout mice, AC6 mRNA RT-qPCR, cAMP ELISA, PKA Western blot, echocardiography

   PMID:27643574

   Open questions at the time

   • Correlation-based pathway placement without direct HSF1-ADCY6 promoter binding evidence
   • Causality of AC6 in the HSF1 cardioprotective phenotype not tested by AC6 manipulation
7. 2018 High

   Identified AC6 as the CFTR-associated cAMP source driving cholera toxin-induced intestinal fluid secretion, defining a diarrheagenic signaling complex.

   Evidence RNA-Seq isoform identification, co-immunoprecipitation, epithelium-specific AC6 knockout mice, ileal loop CTX challenge, and intestinal spheroid CFTR activation assays

   PMID:29903911

   Open questions at the time

   • Structural basis and stoichiometry of the AC6-CFTR interaction not defined
   • Whether the interaction is direct or scaffold-mediated unresolved
8. 2019 High

   Showed direct transcriptional control of ADCY6 by Purβ binding its promoter, coupling glucagon signaling to hepatic glucose production via the ADCY6/cAMP/PKA/CREB pathway.

   Evidence ChIP and luciferase reporter assays, adenoviral Purβ knockdown/overexpression in hepatocytes and db/db mice with metabolic tolerance tests

   PMID:31918924

   Open questions at the time

   • Does not establish whether Purβ regulation of ADCY6 occurs in non-hepatic tissues
   • Cis-element within the promoter not finely mapped
9. 2020 High

   Defined a cAMP-effector mechanism by which AC6 controls ciliary length, inhibiting AMPK to prevent autophagic degradation of the kinesin KIF19A.

   Evidence Epithelium-specific AC6 knockout mice, ciliary length measurement, in vitro AMPK activity assays, KIF19A level and autophagosome localization assays, pharmacological AMPK activation

   PMID:32683324

   Open questions at the time

   • Direct biochemical step from cAMP/PKA to AMPK inhibition not fully mapped
   • Generalizability beyond airway epithelium untested
10. 2023 Medium

    Demonstrated that lipid-raft-localized AC6 generates a compartmentalized cAMP pool with substrate specificity distinct from non-raft AC2, explaining isoform-specific signaling outcomes.

    Evidence AC2 and AC6 overexpression in human airway smooth muscle cells with quantitative phosphoproteomics and STRING analysis

    PMID:36926196

    Open questions at the time

    • Phosphoproteomic targets identified by overexpression, not endogenous loss-of-function
    • Functional consequences of individual phosphosites (e.g., OFD1 Ser899) not validated
11. 2022 Medium

    Linked epigenetic regulation of ADCY6 (TET1-mediated demethylation, antagonized by miR-27a-3p) to suppression of EMT in breast cancer, implicating ADCY6 as a regulated tumor-relevant locus.

    Evidence DNA methylation-specific PCR, bisulfite sequencing, lentiviral miRNA transfection, luciferase target validation, and invasion/migration assays

    PMID:35978806

    Open questions at the time

    • Causal contribution of ADCY6 cyclase activity to the EMT phenotype not directly tested
    • Downstream effectors of ADCY6 in this context unidentified

• The molecular basis distinguishing AC6's cAMP-dependent from cAMP-independent activities, and the structural determinants of its calcium inhibition and CFTR/raft compartmentalization, remain unresolved.
• No structural model of the AC6-CFTR complex
• Effector mediating cAMP-independent cardiac protection unknown
• Mechanism of raft-restricted cAMP pool formation undefined